EA201490825A8 - Tdp-43-специфически связывающие молекулы - Google Patents

Tdp-43-специфически связывающие молекулы

Info

Publication number
EA201490825A8
EA201490825A8 EA201490825A EA201490825A EA201490825A8 EA 201490825 A8 EA201490825 A8 EA 201490825A8 EA 201490825 A EA201490825 A EA 201490825A EA 201490825 A EA201490825 A EA 201490825A EA 201490825 A8 EA201490825 A8 EA 201490825A8
Authority
EA
Eurasian Patent Office
Prior art keywords
tdp
binding molecules
specific binding
specifically binding
variants
Prior art date
Application number
EA201490825A
Other languages
English (en)
Other versions
EA032003B1 (ru
EA201490825A1 (ru
Inventor
Рожер Маттиас Др. Нитш
Кристоф Хок
Мария Грация Баренко Монтрасио
Фабио Монтрасио
Ян Гримм
Жан-Люк Берисвиль
Пол Вейнреб
Янаки Кумарасвами
Омар Куинтеро-Монзон
Original Assignee
Байоджен Айдек Интернэшнл Нейросайенз Гмбх
Юниверсити Оф Цюрих
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Айдек Интернэшнл Нейросайенз Гмбх, Юниверсити Оф Цюрих filed Critical Байоджен Айдек Интернэшнл Нейросайенз Гмбх
Publication of EA201490825A1 publication Critical patent/EA201490825A1/ru
Publication of EA201490825A8 publication Critical patent/EA201490825A8/ru
Publication of EA032003B1 publication Critical patent/EA032003B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Abstract

Целью изобретения является создание новых TDP-43-специфически связывающих молекул, в том числе полипептидов, таких как человеческие антитела, а также фрагментов, производных и их вариантов. Предложены также способы, связанные с этими TDP-43-специфически связывающими молекулами. Анализы, наборы и твердые носители, связанные с TDP-43-специфически связывающими молекулами, в том числе полипептидами, такими как человеческие антитела, также раскрыты. TDP-43-специфически связывающие молекулы, антитела, цепь иммуноглобулина(ов), а также связывающие фрагменты, производные и их варианты могут быть использованы в фармацевтических и диагностических составов для TDP-43 ориентированной иммунотерапии и диагностики, соответственно.
EA201490825A 2011-10-28 2012-10-26 Анти-tdp-43 антитело EA032003B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553113P 2011-10-28 2011-10-28
PCT/IB2012/002905 WO2013061163A2 (en) 2011-10-28 2012-10-26 Tdp-43 specific binding molecules

Publications (3)

Publication Number Publication Date
EA201490825A1 EA201490825A1 (ru) 2015-01-30
EA201490825A8 true EA201490825A8 (ru) 2016-09-30
EA032003B1 EA032003B1 (ru) 2019-03-29

Family

ID=47720540

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490825A EA032003B1 (ru) 2011-10-28 2012-10-26 Анти-tdp-43 антитело

Country Status (18)

Country Link
US (3) US9587014B2 (ru)
EP (2) EP2771359B1 (ru)
JP (3) JP6240611B2 (ru)
KR (2) KR101961508B1 (ru)
CN (1) CN104159918B (ru)
AU (1) AU2012327211C9 (ru)
BR (1) BR112014010161B1 (ru)
CA (2) CA2853412C (ru)
CL (1) CL2014001074A1 (ru)
EA (1) EA032003B1 (ru)
ES (1) ES2883212T3 (ru)
HK (1) HK1201846A1 (ru)
IL (2) IL232219B (ru)
MX (2) MX357678B (ru)
MY (1) MY167795A (ru)
SG (1) SG11201401735WA (ru)
WO (1) WO2013061163A2 (ru)
ZA (1) ZA201403680B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
EP2771359B1 (en) 2011-10-28 2021-05-19 Biogen International Neuroscience GmbH Tdp-43 specific binding molecules
CN105593240A (zh) * 2013-06-11 2016-05-18 保罗·谢勒学院 用于以单氨基酸分辨率确定可突变配体-gpcr结合的方法以及突变配体和gpcr对
WO2015117088A2 (en) 2014-01-31 2015-08-06 Arizona Board Of Regents On Behalf Of Arizona State University Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
CN104497121A (zh) * 2014-08-29 2015-04-08 苏州顺升桥生物科技有限公司 淀粉样蛋白tdp-43及其用途
WO2016053610A1 (en) * 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
EP3200825A4 (en) 2014-10-03 2018-03-21 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
TWI592423B (zh) * 2014-10-03 2017-07-21 中央研究院 可辨識致病性ｔｄｐ－４３之抗體及其用途
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
WO2017111166A1 (ja) * 2015-12-25 2017-06-29 国立大学法人東京農工大学 Ｔｄｐ－４３細胞内存在量関連疾患治療剤
DK3430397T3 (da) 2016-03-14 2022-05-02 Biogen Int Neuroscience Gmbh Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner
WO2018022479A1 (en) 2016-07-25 2018-02-01 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
EP3562840A1 (en) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
JP7211961B2 (ja) * 2017-03-14 2023-01-24 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡに結合する抗体
CA3064785A1 (en) 2017-05-30 2018-12-06 The University Of British Columbia Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto
EA202090555A1 (ru) 2017-08-22 2020-06-08 Байоджен Ма Инк. Фармацевтические композиции, содержащие антитела к бета-амилоиду
US11246857B2 (en) * 2017-12-14 2022-02-15 The Johns Hopkins University Anti-fungal inhibitors
WO2019113711A1 (en) 2017-12-14 2019-06-20 University Of Ottawa Exosome packaging and targeted autophagy
AU2019205090A1 (en) * 2018-01-05 2020-08-06 Ac Immune Sa Misfolded TDP-43 binding molecules
US20210024621A1 (en) * 2018-03-16 2021-01-28 National University Corporation Shiga University Of Medical Science Antibody fragment degrading and removing abnormal tdp-43
TW202019398A (zh) * 2018-06-28 2020-06-01 張翔毓 用於治療或預防構形疾病之方法及藥物篩選方法
CN113508135A (zh) 2018-10-29 2021-10-15 比奥根Ma公司 增强血脑屏障转运的人源化和稳定化的fc5变体
EP3894433A4 (en) * 2018-12-14 2022-08-31 The University of British Columbia ANTIBODIES TO MISFOLDED TDP-43 AND METHODS OF USE
WO2020234473A1 (en) 2019-05-23 2020-11-26 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
CN114514240A (zh) * 2019-08-12 2022-05-17 麦考瑞大学 用于治疗的组合物和方法
GB202004863D0 (en) * 2020-04-02 2020-05-20 Univ Oxford Innovation Ltd Method
EP4143215A2 (en) 2020-04-28 2023-03-08 SOLA Biosciences LLC Compositions and methods for the treatment of tdp-43 proteinopathies
CN115803054A (zh) * 2020-04-29 2023-03-14 英属哥伦比亚大学 针对错误折叠的tdp-43的单链抗体和胞内抗体及其使用方法
AR123254A1 (es) 2020-08-14 2022-11-16 Ac Immune Sa Moléculas de unión anti-tdp-43 humanizadas y usos de las mismas
JP2023551542A (ja) 2020-11-30 2023-12-08 エニグマ バイオインテリジェンス，インコーポレイテッド アルツハイマー病の非侵襲的評価
CN112920264B (zh) * 2021-02-08 2022-07-05 武汉大学 Tdp-43蛋白的o-糖基化突变体及其应用
JP6961278B1 (ja) * 2021-03-10 2021-11-05 国立研究開発法人量子科学技術研究開発機構 生体試料中のｔｄｐ−４３を測定する方法及び装置
EP4351624A1 (en) * 2021-05-27 2024-04-17 Mayo Foundation for Medical Education and Research Methods and materials for treating proteinopathies
CA3231484A1 (en) * 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
WO2023156549A1 (en) 2022-02-16 2023-08-24 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
WO2023194565A1 (en) * 2022-04-08 2023-10-12 Ac Immune Sa Anti-tdp-43 binding molecules
WO2023205579A1 (en) * 2022-04-18 2023-10-26 The Regents Of The University Of California Compositions and methods for disrupting pathological aggregates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688511A (en) * 1991-11-05 1997-11-18 Board Of Regents, The University Of Texas System Cellular protein TDP-43 and regulation of HIV-1 gene expression
EP0934953A2 (en) 1997-12-03 1999-08-11 Boehringer Mannheim Corporation Complex specific antibodies, method of preparation and uses thereof
US8354236B2 (en) * 2006-09-29 2013-01-15 The Trustees Of The University Of Pennsylvania Detection of neurodegenerative disease
CN103408661B (zh) * 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
WO2008151055A1 (en) 2007-06-01 2008-12-11 Mayo Foundation For Medical Education And Research Diagnosing neurodegenerative diseases
US8940872B2 (en) * 2007-07-06 2015-01-27 Tokyo Metropolitan Institute Of Medical Science Antibody binding specifically to TDP-43 aggregate
JP5798322B2 (ja) * 2008-02-01 2015-10-21 ワシントン ユニバーシティ イン セント ルイス Ｔｄｐ−４３蛋白質症に関連した配列およびその使用法
PL2949666T3 (pl) 2008-12-19 2019-07-31 Biogen International Neuroscience Gmbh Ludzkie przeciwciała przeciwko alfa-synukleinie
CN101634656A (zh) * 2009-08-21 2010-01-27 武汉三鹰生物技术有限公司 人tdp-43的单抗包被酶标板的制法及elisa检测试剂盒
EP2771359B1 (en) 2011-10-28 2021-05-19 Biogen International Neuroscience GmbH Tdp-43 specific binding molecules

Also Published As

Publication number Publication date
MX2018008680A (es) 2023-04-18
KR20140100480A (ko) 2014-08-14
WO2013061163A2 (en) 2013-05-02
HK1201846A1 (en) 2015-09-11
JP2017205118A (ja) 2017-11-24
IL270223B (en) 2021-05-31
US20140255304A1 (en) 2014-09-11
AU2012327211C1 (en) 2016-09-15
EP3964524A1 (en) 2022-03-09
JP2015505665A (ja) 2015-02-26
IL232219A0 (en) 2014-06-30
KR20180132977A (ko) 2018-12-12
US11091540B2 (en) 2021-08-17
ES2883212T3 (es) 2021-12-07
SG11201401735WA (en) 2014-05-29
CA2853412C (en) 2021-05-04
BR112014010161B1 (pt) 2022-02-08
NZ624871A (en) 2016-06-24
MX357678B (es) 2018-07-19
EA032003B1 (ru) 2019-03-29
BR112014010161A2 (pt) 2018-09-25
MX2014005048A (es) 2014-11-10
CL2014001074A1 (es) 2015-01-09
KR101961508B1 (ko) 2019-03-25
US20170152308A1 (en) 2017-06-01
MY167795A (en) 2018-09-26
JP6417451B2 (ja) 2018-11-07
US9587014B2 (en) 2017-03-07
CN104159918B (zh) 2019-09-13
CN104159918A (zh) 2014-11-19
JP6240611B2 (ja) 2017-11-29
JP6652609B2 (ja) 2020-02-26
EA201490825A1 (ru) 2015-01-30
AU2012327211A1 (en) 2013-05-23
KR102032080B1 (ko) 2019-10-15
EP2771359A2 (en) 2014-09-03
US10259866B2 (en) 2019-04-16
EP2771359B1 (en) 2021-05-19
CA3112082A1 (en) 2013-05-02
IL232219B (en) 2019-11-28
AU2012327211C9 (en) 2016-11-17
US20200017577A1 (en) 2020-01-16
JP2019022500A (ja) 2019-02-14
ZA201403680B (en) 2020-05-27
CA2853412A1 (en) 2013-05-02
AU2012327211B2 (en) 2016-03-10
WO2013061163A3 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
EA201490825A1 (ru) Tdp-43-специфически связывающие молекулы
PH12021550083A1 (en) Human anti-tau antibodies
EA201390453A1 (ru) Человеческие анти-тау антитела
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
EA201490677A1 (ru) Связывающие антиген cd27l белки
EA201492149A8 (ru) St2-антигенсвязывающие белки
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
ECSP12012272A (es) Proteínas que se unen al tnf-?
EA201391761A1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
EA201270571A1 (ru) Человеческие il-23-антигенсвязывающие белки
EA201390094A1 (ru) ИННОВАЦИОННОЕ ОТКРЫТИЕ ТЕРАПЕВТИЧЕСКИХ КОМПОЗИЦИЙ, ДИАГНОСТИЧЕСКИХ КОМПОЗИЦИЙ И КОМПОЗИЦИЙ АНТИТЕЛ, СВЯЗАННЫХ С БЕЛКОВЫМИ ФРАГМЕНТАМИ АСПАРТИЛ-тРНК-СИНТЕТАЗ
EA201991704A3 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201401065A1 (ru) Ang2-связывающие молекулы
EA202092790A1 (ru) Происходящее от человека антитело к дипептидным повторам (dpr)
DOP2012000266A (es) PROTEÍNAS QUE SE UNEN AL TNF-a
MX360580B (es) Autoanticuerpos humanos anti-alfa-sinucleina.